Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Jens Dannull, Zhen Su, David Rizzieri, Benjamin K. Yang, Doris Coleman, Donna Yancey, Aijing Zhang, Philipp Dahm, Nelson Chao, Eli Gilboa, Johannes Vieweg

Research output: Contribution to journalArticle

820 Citations (Scopus)

Abstract

In this study, we investigated whether elimination of CD4 +/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-transfected DC vaccines. We show that DAB389IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25. DAB389IL-2-mediated Treg depletion resulted in enhanced stimulation of proliferative and cytotoxic T cell responses in vitro but only when DAB389IL-2 was omitted during T cell priming. DAB 389IL-2 significantly reduced the number of Tregs present in the peripheral blood of metastatic renal cell carcinoma (RCC) patients and abrogated Treg-mediated immunosuppressive activity in vivo. Moreover, DAB 389IL-2-mediated elimination of Tregs followed by vaccination with RNA-transfected DCs significantly improved the stimulation of tumor-specific T cell responses in RCC patients when compared with vaccination alone. Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact.

Original languageEnglish
Pages (from-to)3623-3633
Number of pages11
JournalJournal of Clinical Investigation
Volume115
Issue number12
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Regulatory T-Lymphocytes
Immunity
Vaccines
T-Lymphocytes
Renal Cell Carcinoma
Vaccination
RNA
Immunotoxins
Neoplasms
Immunosuppressive Agents
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., ... Vieweg, J. (2005). Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. Journal of Clinical Investigation, 115(12), 3623-3633. https://doi.org/10.1172/JCI25947

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. / Dannull, Jens; Su, Zhen; Rizzieri, David; Yang, Benjamin K.; Coleman, Doris; Yancey, Donna; Zhang, Aijing; Dahm, Philipp; Chao, Nelson; Gilboa, Eli; Vieweg, Johannes.

In: Journal of Clinical Investigation, Vol. 115, No. 12, 01.12.2005, p. 3623-3633.

Research output: Contribution to journalArticle

Dannull, J, Su, Z, Rizzieri, D, Yang, BK, Coleman, D, Yancey, D, Zhang, A, Dahm, P, Chao, N, Gilboa, E & Vieweg, J 2005, 'Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells', Journal of Clinical Investigation, vol. 115, no. 12, pp. 3623-3633. https://doi.org/10.1172/JCI25947
Dannull, Jens ; Su, Zhen ; Rizzieri, David ; Yang, Benjamin K. ; Coleman, Doris ; Yancey, Donna ; Zhang, Aijing ; Dahm, Philipp ; Chao, Nelson ; Gilboa, Eli ; Vieweg, Johannes. / Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. In: Journal of Clinical Investigation. 2005 ; Vol. 115, No. 12. pp. 3623-3633.
@article{98aedec5ed5c4fcfa33154f3f75b38ca,
title = "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells",
abstract = "In this study, we investigated whether elimination of CD4 +/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-transfected DC vaccines. We show that DAB389IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25. DAB389IL-2-mediated Treg depletion resulted in enhanced stimulation of proliferative and cytotoxic T cell responses in vitro but only when DAB389IL-2 was omitted during T cell priming. DAB 389IL-2 significantly reduced the number of Tregs present in the peripheral blood of metastatic renal cell carcinoma (RCC) patients and abrogated Treg-mediated immunosuppressive activity in vivo. Moreover, DAB 389IL-2-mediated elimination of Tregs followed by vaccination with RNA-transfected DCs significantly improved the stimulation of tumor-specific T cell responses in RCC patients when compared with vaccination alone. Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact.",
author = "Jens Dannull and Zhen Su and David Rizzieri and Yang, {Benjamin K.} and Doris Coleman and Donna Yancey and Aijing Zhang and Philipp Dahm and Nelson Chao and Eli Gilboa and Johannes Vieweg",
year = "2005",
month = "12",
day = "1",
doi = "10.1172/JCI25947",
language = "English",
volume = "115",
pages = "3623--3633",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

AU - Dannull, Jens

AU - Su, Zhen

AU - Rizzieri, David

AU - Yang, Benjamin K.

AU - Coleman, Doris

AU - Yancey, Donna

AU - Zhang, Aijing

AU - Dahm, Philipp

AU - Chao, Nelson

AU - Gilboa, Eli

AU - Vieweg, Johannes

PY - 2005/12/1

Y1 - 2005/12/1

N2 - In this study, we investigated whether elimination of CD4 +/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-transfected DC vaccines. We show that DAB389IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25. DAB389IL-2-mediated Treg depletion resulted in enhanced stimulation of proliferative and cytotoxic T cell responses in vitro but only when DAB389IL-2 was omitted during T cell priming. DAB 389IL-2 significantly reduced the number of Tregs present in the peripheral blood of metastatic renal cell carcinoma (RCC) patients and abrogated Treg-mediated immunosuppressive activity in vivo. Moreover, DAB 389IL-2-mediated elimination of Tregs followed by vaccination with RNA-transfected DCs significantly improved the stimulation of tumor-specific T cell responses in RCC patients when compared with vaccination alone. Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact.

AB - In this study, we investigated whether elimination of CD4 +/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-transfected DC vaccines. We show that DAB389IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25. DAB389IL-2-mediated Treg depletion resulted in enhanced stimulation of proliferative and cytotoxic T cell responses in vitro but only when DAB389IL-2 was omitted during T cell priming. DAB 389IL-2 significantly reduced the number of Tregs present in the peripheral blood of metastatic renal cell carcinoma (RCC) patients and abrogated Treg-mediated immunosuppressive activity in vivo. Moreover, DAB 389IL-2-mediated elimination of Tregs followed by vaccination with RNA-transfected DCs significantly improved the stimulation of tumor-specific T cell responses in RCC patients when compared with vaccination alone. Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact.

UR - http://www.scopus.com/inward/record.url?scp=30144444279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144444279&partnerID=8YFLogxK

U2 - 10.1172/JCI25947

DO - 10.1172/JCI25947

M3 - Article

C2 - 16308572

AN - SCOPUS:30144444279

VL - 115

SP - 3623

EP - 3633

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -